Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting

-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity)

-- MDNA11 selectively increased a sub-population of anti-tumor ICOS⁺ CD8 T cells without enhancing proliferation of highly immune-suppressive pro-tumor ICOS⁺ Treg cells